
    
      This study was a multi-center, multinational, prospective, single-arm clinical study with a
      6-month treatment period. The primary objective was to extend the safety database of patients
      with CKD who receive i.v. HX575 epoetin alfa treatment and to monitor the adverse event (AE)
      profile under post-approval conditions.
    
  